Process for increasing the antagonistic effect of peptidic compounds on hormone-dependent diseases
US4835139A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | May 19, 1987 |
| Grant date | May 30, 1989 |
| Priority date | — |
| Expiry date | May 19, 2007 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S930/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The antagonistic effect of the releasing hormone of LH and FSH or of one of its synthetic analogues selected from the group EQU (pyro) Glu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH.sub.2 EQU (pyro) Glu-His-Trp-Ser-Tyr-D-Phe-Leu-Arg-Pro-Gly-NH.sub.2 EQU and EQU (pyro) Glu-His-Trp-D-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHR.sup.1 (R.sup.1 being an alkyl group). On hormone-dependent diseases can be increased by coating such compounds by micro-encapsulation or by matrix formation with a copolymer of a lactide and a glycolide. The initial stimulating effect of the above-mentioned compounds is increased by this coating, with about 23 to 50% of the active principle of the analog being released within about 1-5 days after injection to a human, with the remainder released over a period of between about 3 weeks and two months.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.